Allergan to Acquire Kythera

Allergan has entered into a definitive agreement to acquire Kythera Biopharmaceuticals in a cash and stock transaction valued at $75 per share, or approximately $2.1 billion. Once the transaction is complete, Kythera’s recently approved Kybella (deoxycholic acid) will be part of an aesthetic portfolio that also includes Botox Cosmetic (onabotulinumtoxinA).

According to Joel Schlessinger, MD, Chief Cosmetic Surgery Editor of Practical Dermatology® magazine, the synergies of these two companies are obvious and the additive value that Kybella will offer for the cosmetic patient is significant, as well. “This will dovetail well for all the Botox, Juvederm, and other cosmetic patients in the Allergan fold,” Dr. Schlessinger notes. “Additionally, the immediate reach and pull of Allergan's rewards program, Brilliant Distinctions, will lead to a quick uptake in adoption with these already self-identified cosmetic patients.” 

            Beyond the obvious growth of a wider aesthetic portfolio, Dr. Schlessinger predicts that the transition will likely be quick and efficient from a business perspective, as well. “The integration of these two companies will be easily effected given the fact that many employees come from Allergan and understand the culture and structure of this company,” says Dr. Schlessinger.